Patients' characteristics: N = 84
| Variables . | Median (range) . | No. (%) . |
|---|---|---|
| Age, y | 54 (18-79) | |
| Prior interferon therapy | 80 (95) | |
| Median time from diagnosis to treatment with imatinib, mo | 28 (0-184) | |
| Median duration on imatinib therapy, mo | 20 (3-76) | |
| Best response to imatinib | ||
| Complete hematologic response | 30 (36) | |
| Cytogenetic response | 50 (60) | |
| Major | 38 (45) | |
| Complete | 22 (26) | |
| Disease group at imatinib dose escalation | ||
| Hematologic relapse | 17 (20) | |
| Hematologic resistance | 4 (5) | |
| Cytogenetic relapse | 33 (39) | |
| Loss of CCyR but still in MCyR | 8 (10) | |
| Cytogenetic resistance | 30 (36) | |
| Resistance with no cytogenetic response | 18 (21) | |
| MCyR with no CCyR | 5 (6) | |
| Imatinib dose escalation from | ||
| 400 to 800 mg daily | 72 (86) | |
| 300 to 600 mg daily | 12 (14) | |
| Median follow-up from imatinib escalation, mo | 61 (7-89) | |
| Variables . | Median (range) . | No. (%) . |
|---|---|---|
| Age, y | 54 (18-79) | |
| Prior interferon therapy | 80 (95) | |
| Median time from diagnosis to treatment with imatinib, mo | 28 (0-184) | |
| Median duration on imatinib therapy, mo | 20 (3-76) | |
| Best response to imatinib | ||
| Complete hematologic response | 30 (36) | |
| Cytogenetic response | 50 (60) | |
| Major | 38 (45) | |
| Complete | 22 (26) | |
| Disease group at imatinib dose escalation | ||
| Hematologic relapse | 17 (20) | |
| Hematologic resistance | 4 (5) | |
| Cytogenetic relapse | 33 (39) | |
| Loss of CCyR but still in MCyR | 8 (10) | |
| Cytogenetic resistance | 30 (36) | |
| Resistance with no cytogenetic response | 18 (21) | |
| MCyR with no CCyR | 5 (6) | |
| Imatinib dose escalation from | ||
| 400 to 800 mg daily | 72 (86) | |
| 300 to 600 mg daily | 12 (14) | |
| Median follow-up from imatinib escalation, mo | 61 (7-89) | |
MCyR indicates major cytogenetic response; and CCyR, complete cytogenetic response.